Comparative Pharmacology
Head-to-head clinical analysis: DACOGEN versus INQOVI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DACOGEN versus INQOVI.
DACOGEN vs INQOVI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Decitabine is a hypomethylating agent that incorporates into DNA and inhibits DNA methyltransferase, resulting in hypomethylation of DNA and subsequent gene reactivation.
INQOVI is a combination of decitabine, a hypomethylating agent that inhibits DNA methyltransferase, and cedazuridine, a cytidine deaminase inhibitor that prevents degradation of decitabine, increasing its systemic exposure.
15 mg/m² intravenously over 3 hours every 8 hours for 3 consecutive days, repeated every 6 weeks for a minimum of 4 cycles.
INQOVI (decitabine and cedazuridine) is administered orally once daily on days 1 through 5 of a 28-day cycle. The recommended dose is 1 tablet (35 mg decitabine and 100 mg cedazuridine) taken on an empty stomach.
None Documented
None Documented
Terminal elimination half-life: approximately 1.5 hours at steady state. Short half-life necessitates daily administration in current regimens.
The terminal elimination half-life of decitabine is approximately 2.5 hours (range 1.5-3.5 hours) following oral INQOVI administration. Cedazuridine has a similar half-life of about 2 hours. The half-lives are short, necessitating daily dosing for 5 days per cycle.
Renal excretion of unchanged drug and metabolites: approximately 90% of total clearance. Biliary/fecal excretion: <10%.
Decitabine and cedazuridine are primarily excreted renally. Following oral administration, 58-64% of the decitabine dose and 93% of the cedazuridine dose are recovered in urine, with <2% in feces. Renal excretion is the main elimination pathway for both components.
Category C
Category C
Hypomethylating Agent
Hypomethylating Agent